Cellectis CLLS Stock
Cellectis Price Chart
Cellectis CLLS Financial and Trading Overview
| Cellectis stock price | 3.09 USD |
| Previous Close | 3.52 USD |
| Open | 3.55 USD |
| Bid | 4.26 USD x 100 |
| Ask | 3.64 USD x 100 |
| Day's Range | 3.44 - 3.6 USD |
| 52 Week Range | 1.33 - 5.48 USD |
| Volume | 39.99K USD |
| Avg. Volume | 40.87K USD |
| Market Cap | 350.13M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.67 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.6 USD |
CLLS Valuation Measures
| Enterprise Value | 347.2M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.612903 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.661412 |
| Price/Book (mrq) | 5.838926 |
| Enterprise Value/Revenue | 4.622 |
| Enterprise Value/EBITDA | -10.479 |
Trading Information
Cellectis Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 136.24% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 5.48 USD |
| 52 Week Low | 1.33 USD |
| 50-Day Moving Average | 3.72 USD |
| 200-Day Moving Average | 3.79 USD |
CLLS Share Statistics
| Avg. Volume (3 month) | 40.87K USD |
| Avg. Daily Volume (10-Days) | 38.34K USD |
| Shares Outstanding | 72.61M |
| Float | 64.64M |
| Short Ratio | 14.46 |
| % Held by Insiders | 0% |
| % Held by Institutions | 16.54% |
| Shares Short | 337.44K |
| Short % of Float | 0.61% |
| Short % of Shares Outstanding | 0.33% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -89.50% |
| Operating Margin (ttm) | -333.42% |
| Gross Margin | 100.00% |
| EBITDA Margin | -44.11% |
Management Effectiveness
| Return on Assets (ttm) | -8.43% |
| Return on Equity (ttm) | -76.34% |
Income Statement
| Revenue (ttm) | 75.11M USD |
| Revenue Per Share (ttm) | 0.75 USD |
| Quarterly Revenue Growth (yoy) | -37.20% |
| Gross Profit (ttm) | 75.11M USD |
| EBITDA | -33134000 USD |
| Net Income Avi to Common (ttm) | -67230000 USD |
| Diluted EPS (ttm) | -0.67 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 34.84M USD |
| Total Cash Per Share (mrq) | 0.35 USD |
| Total Debt (mrq) | 32.2M USD |
| Total Debt/Equity (mrq) | 53.74 USD |
| Current Ratio (mrq) | 1.521 |
| Book Value Per Share (mrq) | 0.596 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -37651000 USD |
| Levered Free Cash Flow (ttm) | -53553624 USD |
Profile of Cellectis
| Country | United States |
| State | N/A |
| City | Paris |
| Address | 8, rue de la Croix Jarry |
| ZIP | 75013 |
| Phone | 33 1 81 69 16 00 |
| Website | https://www.cellectis.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 224 |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Q&A For Cellectis Stock
What is a current CLLS stock price?
Cellectis CLLS stock price today per share is 3.09 USD.
How to purchase Cellectis stock?
You can buy CLLS shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cellectis?
The stock symbol or ticker of Cellectis is CLLS.
Which industry does the Cellectis company belong to?
The Cellectis industry is Biotechnology.
How many shares does Cellectis have in circulation?
The max supply of Cellectis shares is 100.61M.
What is Cellectis Price to Earnings Ratio (PE Ratio)?
Cellectis PE Ratio is now.
What was Cellectis earnings per share over the trailing 12 months (TTM)?
Cellectis EPS is -0.67 USD over the trailing 12 months.
Which sector does the Cellectis company belong to?
The Cellectis sector is Healthcare.
Cellectis CLLS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}